Tags

Type your tag names separated by a space and hit enter

[The Washington summit: orange light for genome editing?].
Med Sci (Paris). 2016 Feb; 32(2):217-20.MS

Abstract

The summit organised in early December 2015 considered in depth the various issues (technical, scientific, societal and ethical) raised by the prospect of genome editing using the extremely effective CRISPR system. Germline editing (for therapeutic or "enhancement" purposes) was stated to be irresponsible under current conditions, but the possibility that this could be considered in the future was not excluded; a mechanism for monitoring progress and possibly revising recommendations was proposed.

Authors+Show Affiliations

UMR 7268 ADÉS, Aix-Marseille, Université/EFS/CNRS, Espace éthique méditerranéen, hôpital d'adultes la Timone, 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France - CoReBio PACA, case 901, parc scientifique de Luminy, 13288 Marseille Cedex 09, France.

Pub Type(s)

Journal Article

Language

fre

PubMed ID

26936181

Citation

Jordan, Bertrand. "[The Washington Summit: Orange Light for Genome Editing?]." Medecine Sciences : M/S, vol. 32, no. 2, 2016, pp. 217-20.
Jordan B. [The Washington summit: orange light for genome editing?]. Med Sci (Paris). 2016;32(2):217-20.
Jordan, B. (2016). [The Washington summit: orange light for genome editing?]. Medecine Sciences : M/S, 32(2), 217-20. https://doi.org/10.1051/medsci/20163202017
Jordan B. [The Washington Summit: Orange Light for Genome Editing?]. Med Sci (Paris). 2016;32(2):217-20. PubMed PMID: 26936181.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [The Washington summit: orange light for genome editing?]. A1 - Jordan,Bertrand, Y1 - 2016/03/02/ PY - 2016/3/4/entrez PY - 2016/3/5/pubmed PY - 2016/12/24/medline SP - 217 EP - 20 JF - Medecine sciences : M/S JO - Med Sci (Paris) VL - 32 IS - 2 N2 - The summit organised in early December 2015 considered in depth the various issues (technical, scientific, societal and ethical) raised by the prospect of genome editing using the extremely effective CRISPR system. Germline editing (for therapeutic or "enhancement" purposes) was stated to be irresponsible under current conditions, but the possibility that this could be considered in the future was not excluded; a mechanism for monitoring progress and possibly revising recommendations was proposed. SN - 1958-5381 UR - https://www.unboundmedicine.com/medline/citation/26936181/[The_Washington_summit:_orange_light_for_genome_editing]_ L2 - http://publications.edpsciences.org/10.1051/medsci/20163202017 DB - PRIME DP - Unbound Medicine ER -